Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
David M. Devilbiss
University of Wisconsin Madison, Department: Psychology
Should you be removed from our database? Contact us at [email protected]. Read more below.
NexStep Biomarkers, LLC.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
An outside activity has a nexus with an individual's research activities if the outside activity arises from, relies upon or is related to the academic expertise that qualifies that individual to participate in federally funded research or human subjects research.
The Institution has reasonably determined that the significant financial interest could directly and significantly affect the design, conduct, or reporting of the PHS-funded research and so requires management.
Low-Dose Methylphenidate and the Prefrontal Cortex
Despite the efficacy of psychostimulants in the treatment of attention deficit hyperactivity disorder (ADHD), their abuse potential raises serious concerns about their widespread clinical use. The development of safer treatments is dependent on a thorough understanding of the neural mechanisms that support the procognitive effects of psychostimulants. This proposal will further test the hypothesis the procognitive actions of psychostimulants involve a facilitation of frontostriatal circuit function via drug action within he prefrontal cortex and subsequent increases in catecholamine receptor signaling. Information gained in these studies may lead to development of novel treatment strategies for frontostriatal dysfunction, including ADHD.
Filed on August 26, 2014.
Tell us what you know about David M. Devilbiss's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “David M. Devilbiss”
Name | Institution | Type | Company | Disclosed Value |
---|---|---|---|---|
David M. Devilbiss | University of Wisconsin Madison | Conflict of Interest | NexStep Biomarkers, LLC. | $40,000 - $59,999 |
David M. Devilbiss | University of Wisconsin Madison | Conflict of Interest | Cerora, Inc. | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.